Logo image of FYB.DE

FORMYCON AG (FYB.DE) Stock Fundamental Analysis

FRA:FYB - Deutsche Boerse Ag - DE000A1EWVY8 - Common Stock - Currency: EUR

24.2  -0.2 (-0.82%)

Fundamental Rating

4

Overall FYB gets a fundamental rating of 4 out of 10. We evaluated FYB against 69 industry peers in the Biotechnology industry. FYB has an average financial health and profitability rating. FYB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

FYB had positive earnings in the past year.
FYB had a negative operating cash flow in the past year.
In multiple years FYB reported negative net income over the last 5 years.
FYB had a negative operating cash flow in each of the past 5 years.
FYB.DE Yearly Net Income VS EBIT VS OCF VS FCFFYB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M

1.2 Ratios

The Return On Assets of FYB (6.74%) is better than 92.75% of its industry peers.
FYB's Return On Equity of 11.09% is amongst the best of the industry. FYB outperforms 88.41% of its industry peers.
Industry RankSector Rank
ROA 6.74%
ROE 11.09%
ROIC N/A
ROA(3y)-2.02%
ROA(5y)-3.74%
ROE(3y)0.46%
ROE(5y)-2.68%
ROIC(3y)N/A
ROIC(5y)N/A
FYB.DE Yearly ROA, ROE, ROICFYB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20

1.3 Margins

FYB's Profit Margin of 105.09% is amongst the best of the industry. FYB outperforms 100.00% of its industry peers.
FYB's Profit Margin has improved in the last couple of years.
With a Gross Margin value of 12.46%, FYB perfoms like the industry average, outperforming 47.83% of the companies in the same industry.
FYB's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM N/A
PM (TTM) 105.09%
GM 12.46%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y42.78%
GM growth 3Y9.85%
GM growth 5Y-7.6%
FYB.DE Yearly Profit, Operating, Gross MarginsFYB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

FYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
FYB has more shares outstanding than it did 1 year ago.
FYB has more shares outstanding than it did 5 years ago.
FYB has a better debt/assets ratio than last year.
FYB.DE Yearly Shares OutstandingFYB.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M
FYB.DE Yearly Total Debt VS Total AssetsFYB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

FYB has an Altman-Z score of 1.56. This is a bad value and indicates that FYB is not financially healthy and even has some risk of bankruptcy.
FYB has a better Altman-Z score (1.56) than 66.67% of its industry peers.
FYB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of FYB (0.02) is better than 78.26% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACCN/A
WACC6.97%
FYB.DE Yearly LT Debt VS Equity VS FCFFYB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 2.10 indicates that FYB has no problem at all paying its short term obligations.
FYB has a Current ratio (2.10) which is in line with its industry peers.
A Quick Ratio of 2.06 indicates that FYB has no problem at all paying its short term obligations.
The Quick ratio of FYB (2.06) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.1
Quick Ratio 2.06
FYB.DE Yearly Current Assets VS Current LiabilitesFYB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

FYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 243.11%, which is quite impressive.
Measured over the past years, FYB shows a very strong growth in Earnings Per Share. The EPS has been growing by 44.36% on average per year.
Looking at the last year, FYB shows a very negative growth in Revenue. The Revenue has decreased by -11.42% in the last year.
FYB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.47% yearly.
EPS 1Y (TTM)243.11%
EPS 3YN/A
EPS 5Y44.36%
EPS Q2Q%-616.27%
Revenue 1Y (TTM)-11.42%
Revenue growth 3Y31.34%
Revenue growth 5Y12.47%
Sales Q2Q%-38.59%

3.2 Future

The Earnings Per Share is expected to grow by 22.98% on average over the next years. This is a very strong growth
FYB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 15.40% yearly.
EPS Next Y-144.35%
EPS Next 2Y-45.33%
EPS Next 3Y22.34%
EPS Next 5Y22.98%
Revenue Next Year-23.89%
Revenue Next 2Y-5.61%
Revenue Next 3Y15.67%
Revenue Next 5Y15.4%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FYB.DE Yearly Revenue VS EstimatesFYB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
FYB.DE Yearly EPS VS EstimatesFYB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 6.05, the valuation of FYB can be described as very cheap.
98.55% of the companies in the same industry are more expensive than FYB, based on the Price/Earnings ratio.
FYB's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.80.
The Forward Price/Earnings Ratio is negative for FYB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 6.05
Fwd PE N/A
FYB.DE Price Earnings VS Forward Price EarningsFYB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FYB.DE Per share dataFYB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

FYB's earnings are expected to grow with 22.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)0.14
EPS Next 2Y-45.33%
EPS Next 3Y22.34%

More info and screens

0

5. Dividend

5.1 Amount

FYB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORMYCON AG

FRA:FYB (3/28/2025, 1:03:26 PM)

24.2

-0.2 (-0.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-28 2024-11-28
Earnings (Next)03-27 2025-03-27/amc
Inst Owners11.33%
Inst Owner ChangeN/A
Ins Owners9.2%
Ins Owner ChangeN/A
Market Cap427.37M
Analysts84
Price Target67.69 (179.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-25.25%
PT rev (3m)-26.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-94.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11%
Revenue NY rev (1m)-1.81%
Revenue NY rev (3m)-3.52%
Valuation
Industry RankSector Rank
PE 6.05
Fwd PE N/A
P/S 7.03
P/FCF N/A
P/OCF N/A
P/B 0.74
P/tB 62.42
EV/EBITDA N/A
EPS(TTM)4
EY16.53%
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)-1.85
OCFYN/A
SpS3.44
BVpS32.63
TBVpS0.39
PEG (NY)N/A
PEG (5Y)0.14
Profitability
Industry RankSector Rank
ROA 6.74%
ROE 11.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 105.09%
GM 12.46%
FCFM N/A
ROA(3y)-2.02%
ROA(5y)-3.74%
ROE(3y)0.46%
ROE(5y)-2.68%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y42.78%
GM growth 3Y9.85%
GM growth 5Y-7.6%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1273.47%
Cap/Sales 43.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.1
Quick Ratio 2.06
Altman-Z 1.56
F-Score3
WACC6.97%
ROIC/WACCN/A
Cap/Depr(3y)872.92%
Cap/Depr(5y)553.96%
Cap/Sales(3y)30.94%
Cap/Sales(5y)19.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)243.11%
EPS 3YN/A
EPS 5Y44.36%
EPS Q2Q%-616.27%
EPS Next Y-144.35%
EPS Next 2Y-45.33%
EPS Next 3Y22.34%
EPS Next 5Y22.98%
Revenue 1Y (TTM)-11.42%
Revenue growth 3Y31.34%
Revenue growth 5Y12.47%
Sales Q2Q%-38.59%
Revenue Next Year-23.89%
Revenue Next 2Y-5.61%
Revenue Next 3Y15.67%
Revenue Next 5Y15.4%
EBIT growth 1Y-765.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-170.47%
EBIT Next 3Y166.73%
EBIT Next 5Y67.76%
FCF growth 1Y-223.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-106.26%
OCF growth 3YN/A
OCF growth 5YN/A